down arrow

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001237
  • SHE: 300204
CNY
20.65
-0.24 (-1.15%)

Sep 22

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Why is Staidson (Beijing) Biopharmaceuticals Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 0%
  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of -15.81% and Operating profit at 8.53% over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
  • INTEREST(HY) At CNY 7.11 MM has Grown at 1,317.96%
  • NET SALES(Q) At CNY 46.9 MM has Fallen at -25.81%
  • PRE-TAX PROFIT(Q) At CNY -9.47 MM has Fallen at -117.27%
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -45.88%, its profits have risen by 37.3%
5
Underperformed the market in the last 1 year
  • Even though the market (China Shanghai Composite) has generated returns of 16.83% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -45.88% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Staidson (Beijing) Biopharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
-43.13%
4.23
74.09%
China Shanghai Composite
3.23%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-15.81%
EBIT Growth (5y)
8.53%
EBIT to Interest (avg)
-168.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.30
Tax Ratio
0.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.02
EV to EBIT
-111.95
EV to EBITDA
-141.23
EV to Capital Employed
12.15
EV to Sales
47.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.85%
ROE (Latest)
-11.48%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY -96.45 MM

NET PROFIT(HY)

Higher at CNY -36.77 MM

-28What is not working for the Company
INTEREST(HY)

At CNY 7.47 MM has Grown at 1,151.38%

NET SALES(Q)

At CNY 46 MM has Fallen at -26.26%

RAW MATERIAL COST(Y)

Grown by 10.31% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 30.94 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.84 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

NET PROFIT(Q)

Fallen at -27.06%

Here's what is working for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Operating Cash Flow
Highest at CNY -96.45 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Here's what is not working for Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Interest
At CNY 7.47 MM has Grown at 1,151.38%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales
At CNY 46 MM has Fallen at -26.26%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Profit
Fallen at -27.06%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

Debt-Equity Ratio
Highest at 30.94 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio
Lowest at 2.84 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 10.31% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading